Get started
Nuvectis Pharma, Inc.Nuvectis Pharma, Inc.Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc.

No trades
See on Supercharts
Overview
Financials
News Ideas Discussions Technicals Forecast Seasonals Options

NVCT fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its product pipeline includes NXP800 and NXP900. The company was founded by Ronald E. Bentsur, Enrique Poradosu, and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
NVCT has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company